Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs TeraWulf Inc (WULF) Price & Performance

Amylx Pharmaceuticals IncTrade
TeraWulf IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs TeraWulf Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while TeraWulf Inc trades at $17.19 (market cap $8.35B). The key difference: TeraWulf Inc is far larger — about 3.2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals.

AMLXWULF
Market Cap
$2.64B$8.35B
Sector
HealthTechnology
52-Week High
$24.19$28.98
52-Week Low
$7.82$5.24
Enterprise Value
$2.39B$10.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.

The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.

TeraWulf Inc

WULF trades at $17.19, up 6.11% today amid a broader neocloud sector rally. The stock shows bearish technical signals with negative earnings trends, posting significant losses in recent quarters. Despite strong analyst consensus (14 buy ratings, 0 hold/sell), fundamental metrics reveal challenges with a P/S of 43.81, P/B of 56.71, and deeply negative profit margins. Recent news highlights the company's pivot to high-performance computing with a major Anthropic deal and 102 MW of operational capacity.

The outlook remains speculative with high execution risks and substantial capital requirements. While analyst price targets average $38.00 (121% upside potential), investors face volatility from ongoing losses, construction cost pressures, and regulatory exposure to New York's data-center moratorium. The stock's performance will depend on successful HPC expansion and profitability improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About TeraWulf Inc

TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.

Read more on WULF